Table 3.
Parameter | Variable | Median (25%–75% Percentiles) for: | P | |
---|---|---|---|---|
Participants With Good Improvement While On Medication (>5%) (n = 14) | Participants With Less or No Improvement While On Medication (<5%) (n = 14) | |||
Participant characteristics and disease severity | Age, y | 70.00 (65.25–73.00) | 71.00 (63.50–75.00) | .93 |
Sex, % women | 14.3 | 42.9 | .94 | |
Disease duration, y | 14.00 (9.50–18.00) | 9.50 (6.13–17.00) | .44 | |
MDS-UPDRS part III while off medicationb | 50.50 (35.25–53.00) | 45.00 (35.00–50.25) | .34 | |
MDS-UPDRS part III while on medicationb | 37.00 (29.25–44.75) | 32.50 (24.75–38.00) | .48 | |
MDS-UPDRS III, item 3.11 FOG, while off medicationb | 2.00 (0.00–3.25) | 2.00 (0.00–2.00) | .28 | |
MDS-UPDRS III, item 3.11 FOG, while on medicationb | 1.00 (0.00–2.00) | 1.50 (0.00–2.00 | .55 | |
Hoehn and Yahr stage | 2.00 (1.50–2.13) | 2.00 (1.88–2.00) | .55 | |
Gait speed during 4-m walk, m/s | 1.15 (1.00–1.23) | 0.94 (0.85–1.14) | .04 | |
LEDD, mg/d | 832.50 (668.75–1653.75) | 630.00 (311.25–1012.50) | .03 | |
Unsupervised home monitoring | %TF during monitoring | 2.8 (0.9–3.1) | 0.6 (0.5–1.2) | .01 |
No. of FOG episodes | 876.00 (420.50–1491.25) | 456.50 (265.75–525.50) | .01 | |
No. of FOG episodes/h | 35.43 (14.93–43.64) | 11.94 (8.76–22.09) | .02 | |
Daily usage of home monitoring device, min | 221.90 (167.42–338.50) | 223.55 (191.12–366.79) | .41 | |
Amount of FOG during supervised FOG-provoking tests (%TF) while off medication | 4-m walk while off medicationc | 2.4 (0.0–20.6) | 0.0 (0.0–0.0) | .03 |
TUG, single task, while off medicationc | 2.7 (0.0–20.8) | 0.0 (0.0–6.7) | .20 | |
TUG, dual task, while off medicationc | 3.86 (0.0–41.9) | 0.0 (0.0–4.4) | .07 | |
Turning task, single task, while off medicationc | 42.7 (17.9–66.0) | 9.1 (3.3–47.4) | .05 | |
Turning task, dual task, while off medicationc | 43.2 (19.3–83.6) | 8.4 (0.0–48.2) | .03 | |
Hot spot, narrow space, while off medicationc | 8.8 (0.0–32.7) | 0.9 (0.0–21.5) | .38 | |
Personal hot spot while off medicationc | 31.0 (12.3–44.6) | 4.8 (0.0–15.2) | ≤.001d | |
Total %TF during provoking protocol while off medicationc | 39.5 (17.4–47.6) | 8.8 (3.5–30.8) | .01 | |
No. of FOG episodes/h while off medication | 259.00 (142.97–320.13) | 154.94 (66.01–180.96) | .01 | |
Amount of FOG during supervised FOG-provoking tests (%TF) while on medication | 4-m walk while on medicationc | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | .32 |
TUG, single task, while on medicationc | 0.0 (0.0–0.0) | 0.0 (0.0–1.5) | .31 | |
TUG, dual task, while on medicationc | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | .78 | |
Turning task, single task, while on medicationc | 0.0 (0.0–39.8) | 8.9 (0.0–57.8) | .56 | |
Turning task, dual task, while on medicationc | 0.0 (0.0–50.3) | 9.6 (0.0–47.6) | .64 | |
Hot spot, narrow space, while on medicationc | 0.0 (0.0–0.0) | 0.0 (0.0–1.5) | .41 | |
Personal hot spot while on medicationc | 0.0 (0.0–6.9) | 0.0 (0.0–4.7) | .80 | |
Total %TF during provoking protocol while on medicationc | 3.1 (0.0–3.1) | 6.2 (0.0–38.4) | .38 | |
No. of FOG episodes/h while on medication | 66.53 (0.00–203.78) | 173.20 (0.00–242.40) | .59 | |
Self-report questionnaires | New Freezing of Gait Questionnaireb | 23.50 (20.75–26.00) | 20.00 (18.50–24.00) | .04 |
Characterizing Freezing of Gait Questionnaireb | 27.00 (19.50–37.75) | 22.50 (15.75–33.25) | .39 |
Unadjusted P values are shown. FOG = freezing of gait; LEDD = levodopa equivalent daily dose; MDS-UPDRS = Movement Disorders Society Unified Parkinson’s Disease Rating Scale; %TF = percentage of time spent frozen; TUG = Timed “Up & Go” Test.
Reported as a score.
Reported as percentage of time spent frozen.
Statistically significant after adjustment for multiple comparisons.